We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 20% above its sector, the market expects faster growth.
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, delivers extensive healthcare services across Germany, encompassing inpatient, day-patient, and outpatient treatment models. The company's hospitals provide a broad spectrum of medical and surgical care, including cardiovascular rehabilitation, specialized hand and trauma surgery, neurological and psychosomatic treatments, addiction therapy, ophthalmology, and dentistry. They also address conditions affecting the thoracic region, lungs, and vascular system, offer oncology services, and manage neurological conditions, spinal column and joint issues, as well as heart diseases. The organization operates eight hospitals, providing a total of 5,420 beds or patient slots across five distinct medical locations. RHÖN-KLINIKUM is headquartered in Bad Neustadt an der Saale, Germany.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save RHK.DE and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
